Could a wakefulness drug beat fatigue in IBD patients?
NCT ID NCT07582458
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether modafinil, a drug used for sleep disorders, can reduce severe fatigue in adults with inactive inflammatory bowel disease (IBD). Sixty participants will take either modafinil or a placebo for 8 weeks, starting at 100 mg daily with possible dose increases. The main goal is to see if fatigue scores improve more with modafinil than with placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Modafinil
- What this could lead to
- If it works, this could offer a new treatment option for severe fatigue in people with inactive inflammatory bowel disease.
- What could go wrong
- This is a small, early-phase trial (Phase 2/3) with only 60 participants. The drug may not prove more effective than placebo, and side effects like headache or anxiety are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC FATIGUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a Real-World study reveal the staying power of guselkumab?